Skip to main content

Eye Conditions News (Page 4)

Related terms: Eye Disorders

Robotic Procedure Helps Treat Macular Degeneration

THURSDAY, June 12, 2024 – Robot-guided radiation therapy can improve treatment for age-related macular degeneration, the leading cause of vision loss and blindness among American seniors, a new...

Neighborhood Inequity Tied to More People Living With Vision Difficulty, Blindness

TUESDAY, May 14, 2024 – Residential measures of inequity are associated with a greater number of individuals living with vision difficulty and blindness (VDB), according to a study published online...

Gene Therapy Improves Vision in People With Inherited Blindness

MONDAY, May 6, 2024 – An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindness, an early-stage clinical trial says. Researchers...

FDA Medwatch Alert: Brassica Pharma Pvt. Ltd. Issues Voluntary Nationwide Recall of Eye Ointment Products Due to Potential Lack of Sterility

22 February, 2024 – Thane, Maharashtra, India, Brassica Pharma Pvt. Ltd. is voluntarily recalling Eye Ointment products listed in the table below with expiration date ranging from February 2024 to S...

FDA Medwatch Alert: FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

September 12, 2023 – The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal...

FDA Medwatch Alert: Dr. Berne’s Whole Health Products Issues Voluntary Nationwide Recall of Dr. Berne’s MSM Drops 5% and 15% Solution Eye Drops Due to Bacterial and Fungal Contamination

August 26, 2023 – Dr. Berne’s Whole Health Products is voluntarily recalling all lots of MSM DROPS 5%,15% Solution, Dr. Berne’s Organic Castor Oil Eye Drops and Dr. Berne’s MSM MIST 15% Solution to t...

FDA Medwatch Alert: FDA Warns Consumers Not To Purchase or Use Certain Methylsulfonylmethane (MSM) Eye Drops Due to Contamination

August 22, 2023 – FDA is warning consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops – Eye Repair due to bacterial contamination, fun...

FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of Geographic Atrophy, a Leading Cause of Blindness

WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and...

FDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults

BRIDGEWATER, N.J, July 09, 2020 (GLOBE NEWSWIRE) – Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that the U....

FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery

BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for d...

FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis

WATERTOWN, Mass., Oct. 15, 2018 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...

FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis

WATERTOWN, Mass., Oct. 15, 2018 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...

FDA Approves Xelpros (latanoprost ophthalmic emulsion) to Treat Open-angle Glaucoma or Ocular Hypertension

MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE) September 14, 2018 --Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) today announced U.S. Food and Drug...

FDA Approves Oxervate (cenegermin) for Neurotrophic Keratitis

August 22, 2018 – The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the...

Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery

Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care th...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Glaucoma, Eye Dryness / Redness, Macular Degeneration, Cataract, Macular Edema

Related drug support groups

Rocephin